@SightGlassVis profile picture
SightGlass Vision, Inc. @SightGlassVis

Our medical device company is developing spectacle lenses to slow the progression of myopia (nearsightedness) in children.

Joined April 2019
  • Tweets 31
  • Following 13
  • Followers 28
25 Photos and videos
Experiencing SightGlass Vision’s Spectacle Lenses - reviewofmm.com/initial-clini…

Experiencing SightGlass Vision’s Spectacle Lenses

December 15, 2021 By Joe Rappon, OD, MS, FAAO, and Kylvin Ho, OD, FIAOMC As children continue to develop myopia at earlier ages, and being that we can only slow the progression of myopia (not reverse...

reviewofmm.com
1
Excited to share this article from @PCONews about the growing #myopia epidemic and how our novel DOT spectacle lenses are designed to slow #myopia progression in children. bit.ly/2DiAdjR

SightGlass targets global myopia progression with new spectacles

Executives from SightGlass Vision, developers of novel spectacles designed to slow myopia progression in children, are hoping this treatment option can help address the increasing prevalence of this...

healio.com
3
Check out this article @MassDevice about achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow #myopia progression in children. bit.ly/3fCl3nt
1
1
Thank you Review of #Myopia Management for this article about our CE Mark achievement for our novel DOT spectacles lenses for myopia management in children. bit.ly/37JHnIZ
1
2
Check out this @EyewireTV segment about our suite of novel DOT spectacle lenses designed to slow #myopia progress in children and achieving CE Mark allowing European Marketing Authorization. bit.ly/2N8MWHt
1
3
Excited to share this article from #FierceBiotech about achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow #myopia progression in children. bit.ly/3efrSev
1
1
Excited to share this WSJ.com article about #myopia that features @SightGlassVis and our novel DOT spectacle lenses. on.wsj.com/30jwRqo
1
1
Achieving CE Mark allowing European Marketing Authorization for our suite of novel DOT spectacle lenses designed to slow the progression of #myopia in children is an important leap forward for our Company, as we advance our mission to end #myopia. prn.to/2ADopYo
2
2
4
We now have definitive data to show that our novel eyeglasses reduce the progression of nearsightedness in children. Check out this article in #Eyewire about our #CYPRESS pivotal trial topline data. bit.ly/2LbUSqB
1
1
Check out this Optometric Management article about our #CYPRESS pivotal trial in #myopia. Topline 1-yr results showed both test arms met superiority in terms of cycloplegic SER change from baseline and axial length change from baseline.
1
1
Excited to share this article from #Healio Primary Care Optometry News about topline data from our #CYPRESS pivotal trial investigating our novel eyeglasses for #myopia in children. bit.ly/35JE1ES
1
2
Check out the topline data from our #CYPRESS pivotal trial investigating our novel eyeglasses for #myopia in children. Results showed both test arms met superiority in terms of cycloplegic SER change from baseline and axial length change from baseline. prn.to/3eWLiFK
1
Thanks to Optical Journal bit.ly/2RqUEiU and Eyewire News bit.ly/34njllF for writing about the positive data from our #CYPRESS pivotal trial investigating our novel spectacle lenses for #myopia in children.
1
3
Check out the write up about our #CYPRESS pivotal trial investigating novel eyeglasses for #myopia in children in Review of Myopia Management bit.ly/2UVFjsI.
1
2
Excited to share this article from Optometric Management about our #CYPRESS pivotal trial of novel eyeglasses for #myopia in children.
1
1
SightGlass Vision, Inc. retweeted
Eyecare Business Mag@eyecarebusiness
7 Apr 2020
.@SightGlassVis shared results from an interim analysis of the its trial evaluating its eyeglasses designed to slow the progression of #myopia in children. The clinical trial showed that both test arms demonstrated a reduction in myopia progression: bit.ly/2x34GzU.
2
2
We're excited to announce that a planned interim analysis from our #CYPRESS pivotal clinical trial of novel eyeglasses designed to control #nearsightedness (#myopia) demonstrated successful reduction of myopia progression in children. Click here prn.to/2xG3yC4 for info
3
Check out Joe Rappon, OD, MS, FAAO, Chief Medical Officer at SightGlass Vision, on camera interview with Helio at the World Congress of Optometry 2019 #myopia healio.com/optometry/pediatr…
1
#ICYMI: We presented data from our three studies overviewing discovery to clinical development of our novel lenses to control #myopia in children – PALM (pilot), WALNUT (preliminary), CYPRESS (pivotal) – at Academy 2019 & 3rd #WCOCongress19. prn.to/2JhJj0D. #myopia
1
3
We look forward to presenting for the first time data that tell the whole story of our novel lenses to control nearsightedness in children – from concept to the clinic – at Academy 2019 & 3rd World Congress of Optometry. prn.to/2JhJj0D. #myopia #Academy19 #WCOCongress19
1
Load more